Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)
Latest Information Update: 13 Jun 2025
At a glance
- Drugs BGC-101-BioGenCell (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial occlusive disorders
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms EnEPC-CLI
- Sponsors BioGenCell
Most Recent Events
- 06 Jun 2025 Planned number of patients changed from 50 to 40.
- 19 Dec 2024 Status changed from recruiting to active, no longer recruiting, according to a BioGenCell media release.
- 19 Dec 2024 According to a BioGenCell media release, phase 2 trial has completed patient recruitment.